Literature DB >> 25437964

Current dystrophic epidermolysis bullosa research does not match research needs perceived by patients and clinicians.

Paula Davila-Seijo1, Ángela Hernández-Martín2, Evanina Morcillo-Makow3, Catriona Rajan4, Ignacio García-Doval5.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25437964     DOI： 10.1016/j.jaad.2014.05.038

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  3 in total

1.  Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms.

Authors:  Alexander Nyström; Kerstin Thriene; Venugopal Mittapalli; Johannes S Kern; Dimitra Kiritsi; Jörn Dengjel; Leena Bruckner-Tuderman
Journal:  EMBO Mol Med       Date:  2015-09       Impact factor: 12.137

2.  Betulin-Based Oleogel to Improve Wound Healing in Dystrophic Epidermolysis Bullosa: A Prospective Controlled Proof-of-Concept Study.

Authors:  Agnes Schwieger-Briel; Dimitra Kiritsi; Christoph Schempp; Cristina Has; Hauke Schumann
Journal:  Dermatol Res Pract       Date:  2017-05-22

3.  Identification of a novel homozygous LAMB3 mutation in a Chinese male with junctional epidermolysis bullosa and severe urethra stenosis: A case report.

Authors:  Wei Wang; Qiang Guo; Jinshan Chen; Xi Zhang; Chengyong Li; Shuangping Li; Jialin Liang; Chuan Hao; Jingqi Wang
Journal:  Front Genet       Date:  2022-09-30       Impact factor: 4.772
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.